(Q28082259)

A Ribas

series ordinal

2

1 reference

British Journal of Cancer

language of work or name

1 reference

28 April 2015

13 references

3 April 2019

18 June 2019

19 June 2019

25 June 2019

31 July 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

9 September 2020

8 February 2021

17 October 2022

13 references

3 April 2019

18 June 2019

19 June 2019

25 June 2019

31 July 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

9 September 2020

8 February 2021

17 October 2022

112

1 reference

issue

9

1 reference

page(s)

1421-7

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

copyright license

12 references

3 April 2019

18 June 2019

19 June 2019

25 June 2019

31 July 2019

27 September 2019

27 November 2019

13 December 2019

15 December 2019

9 September 2020

8 February 2021

on focus list of Wikimedia project

17 October 2022

ScienceSource

0 references

cites work

Nivolumab plus ipilimumab in advanced melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

The blockade of immune checkpoints in cancer immunotherapy

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

A small-cell lung cancer genome with complex signatures of tobacco exposure

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

CD28/B7 system of T cell costimulation

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

20 March 2017

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

20 March 2017

https://api.crossref.org/works/10.1038%2FBJC.2015.124

7 January 2021

inferred from DOI database lookup

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-1 blockade induces responses by inhibiting adaptive immune resistance

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

CTLA-4 control over Foxp3+ regulatory T cell function

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade

24 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-L1 expression in triple-negative breast cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Inhibitory B7-family molecules in the tumour microenvironment

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-1 and PD-1 ligands: from discovery to clinical application

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Checkpoint blockade in cancer immunotherapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Screening for familial ovarian cancer: a ray of hope and a light to steer by.

29 September 2017

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

Diagnosis of primary CNS melanoma with neuroimaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

Achieving the best of both worlds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

IL-18 Induces PD-1-Dependent Immunosuppression in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4453674

PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis

27 November 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25856776

12 December 2020

inferred from PubMed ID database lookup

Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25856776

12 December 2020

inferred from PubMed ID database lookup

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

7 January 2021

inferred from DOI database lookup

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2015.124

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/BJC.2015.124

1 reference

Dimensions Publication ID

1031527720

0 references

1 reference

1 reference

PubMed publication ID

25856776

1 reference